Analysts at Canaccord Genuity downgraded Insulet Corporation (NASDAQ: PODD) from Buy to Hold.
The price target for Insulet has been lowered from $38 to $35.
Insulet shares have dropped 27.56% over the past 52 weeks, while the S&P 500 index has...
In a report published Friday, Oppenheimer analyst Steven Lichtman reiterated an Outperform rating on Insulet Corporation (NASDAQ: PODD), but lowered the price target from $50.00 to $39.00.
In the report, Oppenheimer noted, “Comments by PODD...
NEW YORK (TheStreet) -- Shares of Insulet Corp.
fell to a 52-week low of $27.02 today before recovering to $30.63 after JPMorgan downgraded the company to "neutral" from "overweight," and cut its price target to $35 from $45 following...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Insulet (PODD):
Insulet (PODD) is competing against Mini Med, a division of Medtronic, for the insulin delivery system segment. The product has a needle which is inserted until an audible sound is heard, then the needle withdraws leaving behind a tethlon tube. Insuline is dripped from the pod into the body via the tube. When the pod is low on the solution, more is added. This avoids the nasty needle sticks many diabetics loath.
The pod can be worn many places on the body and has no major tubes of complicated computer readouts, vs. the typical insulin pump.
Often a physician asks the patient to try wearing the pod while it drips saline. Uptake is high afterwards as the pod is so comfortable.
Per the CEO, Duane Desisto, they may have a pump company burried in a pod company. Meaning that other drugs may be delivered via the pod.